BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33189595)

  • 1. Risk factors for medication-related osteonecrosis of the jaw and salivary IL-6 IN cancer patients.
    Kemp APT; Ferreira VHC; Mobile RZ; Brandão TB; Sassi LM; Zarpellon A; Braz-Silva PH; Schussel JL
    Braz J Otorhinolaryngol; 2022; 88(5):683-690. PubMed ID: 33189595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survey of Korean dentists on the awareness on bisphosphonate-related osteonecrosis of the jaws.
    Yoo JY; Park YD; Kwon YD; Kim DY; Ohe JY
    J Investig Clin Dent; 2010 Nov; 1(2):90-5. PubMed ID: 25427263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws.
    Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M
    Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.
    Sobczak-Jaskow H; Kochańska B; Drogoszewska B
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374277
    [No Abstract]   [Full Text] [Related]  

  • 5. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bisphosphonate-related osteonecrosis of the jaws].
    Sogacheva VV; Syomkin VA
    Stomatologiia (Mosk); 2022; 101(6):85-90. PubMed ID: 36562373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dental implications of bisphophonate-related osteonecrosis.
    Saldanha S; Shenoy VK; Eachampati P; Uppal N
    Gerodontology; 2012 Sep; 29(3):177-87. PubMed ID: 22486711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
    Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
    Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preserving the oral health of patients on antiresorptive drugs].
    Tilotta F; Folliguet M; Radoï L
    Rev Prat; 2023 Apr; 73(4):421-429. PubMed ID: 37289162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bisphosphonate-related osteonecrosis of the jaw].
    Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
    Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bisphosphonate-associated osteonecrosis of the jaws in lung cancer patients].
    Neves I; Morais A; Magalhães A
    Rev Port Pneumol; 2013; 19(5):228-32. PubMed ID: 23830508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate-related osteonecrosis of the jaws: Report of a case using conservative protocol.
    Heggendorn FL; Leite TC; Cunha KS; Junior AS; Gonçalves LS; da Costa KB; Dias EP
    Spec Care Dentist; 2016 Jan; 36(1):43-7. PubMed ID: 26782365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws.
    Carlson ER; Basile JD
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate-related osteonecrosis of the jaws--a case report.
    Kamoh AK; Ogle O
    Compend Contin Educ Dent; 2012 May; 33(5):e74-7. PubMed ID: 23268588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition.
    Melo MD; Obeid G
    J Am Dent Assoc; 2005 Dec; 136(12):1675-81. PubMed ID: 16383049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of metastatic cancer presenting in osteonecrosis of the jaws (MC-ONJ) in patients undergoing antiresorptive and/or antiangiogenic therapy for skeletal-related adverse events.
    Sacco R; Woolley J; Yates J; Calasans-Maia MD; Akintola O; Patel V
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Jun; 131(6):650-659. PubMed ID: 33518491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life in patients affected by medication-related osteonecrosis of the jaws: A systematic review.
    Bensi C; Giovacchini F; Lomurno G; Eramo S; Barraco G; Tullio A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):182-189. PubMed ID: 33934955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.